{"id":"W4281719812","doi":"10.1016/j.currproblcancer.2022.100875","title":"Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence","year":2022,"lang":"en","type":"review","venue":"Current Problems in Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"Ipsen; Clovis Oncology; Roche; Merck; Janssen Pharmaceuticals; Bayer; AstraZeneca","keywords":"Pembrolizumab; Medicine; Sunitinib; Lenvatinib; Internal medicine; Oncology; Axitinib; Renal cell carcinoma; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001112241,0.001271114,0.007517709,0.002223333,0.0001053356,0.00006002673,0.000709064,0.0002865241,0.0024104],"category_scores_gemma":[0.0001214718,0.0009690411,0.005083192,0.004331982,0.00009007795,0.0002777851,0.0004848705,0.002209031,0.00002897578],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006425527,"about_ca_system_score_gemma":0.002822654,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001060463,"about_ca_topic_score_gemma":0.0009495978,"domain_scores_codex":[0.9924622,0.0007611913,0.002296356,0.002109926,0.001316728,0.001053648],"domain_scores_gemma":[0.9963471,0.0005616886,0.001225168,0.001450137,0.0001190325,0.0002968233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001989753,0.001387595,0.002129588,0.09990836,0.0282895,0.0005410428,0.0007559061,0.002286821,0.00000854579,0.00001648681,0.0003538054,0.8641234],"study_design_scores_gemma":[0.001655339,0.0003980019,0.0002427727,0.007150504,0.320126,0.00004501266,0.00002323061,0.00005811646,0.00001666834,0.00001856397,0.669345,0.0009208122],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003602219,0.9927505,0.00003326642,0.0000647276,0.0004667545,0.00554494,0.0002779808,0.00004911675,0.0004524489],"genre_scores_gemma":[0.008314234,0.9722605,0.0002272686,0.0000246969,0.0001377641,0.01720737,0.0004379339,0.0001499603,0.00124031],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8632026,"threshold_uncertainty_score":0.999276,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5262294098724305,"score_gpt":0.447444856489776,"score_spread":0.0787845533826545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}